Trials / Completed
CompletedNCT01930461
Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma
A Dose Ranging Study Investigating the Efficacy and Safety of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 386 (actual)
- Sponsor
- Stallergenes Greer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the efficacy and safety of different doses of sublingual tablets of house dust mite allergen extracts as compared to placebo in adults with house dust mite-associated allergic asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | SLIT tablets of HDM allergen extracts, 3 different doses (A) | Two sublingual tablets daily for 13 months |
| BIOLOGICAL | SLIT tablets of HDM allergen extracts, 3 different doses (B) | Two sublingual tablets daily for 13 months |
| BIOLOGICAL | SLIT tablets of HDM allergen extracts, 3 different doses (C) | Two sublingual tablets daily for 13 months |
| BIOLOGICAL | Placebo matching the SLIT tablets of HDM allergen extracts | Two sublingual tablets daily for 13 months |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2015-06-01
- Completion
- 2015-08-01
- First posted
- 2013-08-29
- Last updated
- 2015-12-18
Locations
5 sites across 3 countries: France, Germany, Poland
Source: ClinicalTrials.gov record NCT01930461. Inclusion in this directory is not an endorsement.